These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 17505004

  • 1. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
    Choe MS, Chen Z, Klass CM, Zhang X, Shin DM.
    Clin Cancer Res; 2007 May 15; 13(10):3015-23. PubMed ID: 17505004
    [Abstract] [Full Text] [Related]

  • 2. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
    Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM.
    Clin Cancer Res; 2004 Sep 01; 10(17):5930-9. PubMed ID: 15355926
    [Abstract] [Full Text] [Related]

  • 3. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
    Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR, Shin DM.
    Clin Cancer Res; 2005 Sep 01; 11(17):6261-9. PubMed ID: 16144930
    [Abstract] [Full Text] [Related]

  • 4. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 5. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2003 Apr 01; 9(4):1566-72. PubMed ID: 12684433
    [Abstract] [Full Text] [Related]

  • 6. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
    Park JS, Jun HJ, Cho MJ, Cho KH, Lee JS, Zo JI, Pyo H.
    Clin Cancer Res; 2006 Aug 15; 12(16):4989-99. PubMed ID: 16914589
    [Abstract] [Full Text] [Related]

  • 7. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A.
    Clin Cancer Res; 2006 Jan 15; 12(2):617-25. PubMed ID: 16428508
    [Abstract] [Full Text] [Related]

  • 8. Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839.
    Zanchi C, Zuco V, Lanzi C, Supino R, Zunino F.
    Cancer Res; 2005 Mar 15; 65(6):2364-72. PubMed ID: 15781651
    [Abstract] [Full Text] [Related]

  • 9. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
    Teraishi F, Kagawa S, Watanabe T, Tango Y, Kawashima T, Umeoka T, Nisizaki M, Tanaka N, Fujiwara T.
    FEBS Lett; 2005 Aug 01; 579(19):4069-75. PubMed ID: 16023108
    [Abstract] [Full Text] [Related]

  • 10. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S, Budillon A.
    J Cell Physiol; 2003 Apr 01; 195(1):139-50. PubMed ID: 12599217
    [Abstract] [Full Text] [Related]

  • 11. Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma.
    Saigal B, Glisson BS, Johnson FM.
    Anticancer Drugs; 2008 Jun 01; 19(5):465-75. PubMed ID: 18418213
    [Abstract] [Full Text] [Related]

  • 12. Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis.
    Winters ME, Mehta AI, Petricoin EF, Kohn EC, Liotta LA.
    Cancer Res; 2005 May 01; 65(9):3853-60. PubMed ID: 15867384
    [Abstract] [Full Text] [Related]

  • 13. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Thomas SM, Ogagan MJ, Freilino ML, Strychor S, Walsh DR, Gooding WE, Grandis JR, Zamboni WC.
    Mol Pharmacol; 2008 Mar 01; 73(3):627-38. PubMed ID: 18025070
    [Abstract] [Full Text] [Related]

  • 14. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G.
    Clin Cancer Res; 2003 Jun 01; 9(6):2316-26. PubMed ID: 12796401
    [Abstract] [Full Text] [Related]

  • 15. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
    Hashitani S, Urade M, Nishimura N, Maeda T, Takaoka K, Noguchi K, Sakurai K.
    Int J Oncol; 2003 Sep 01; 23(3):665-72. PubMed ID: 12888902
    [Abstract] [Full Text] [Related]

  • 16. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wirth LJ, Haddad RI, Lindeman NI, Zhao X, Lee JC, Joshi VA, Norris CM, Posner MR.
    J Clin Oncol; 2005 Oct 01; 23(28):6976-81. PubMed ID: 16172459
    [Abstract] [Full Text] [Related]

  • 17. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
    Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, Dimitroulakos J.
    Clin Cancer Res; 2005 Mar 15; 11(6):2398-407. PubMed ID: 15788691
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Shintani S, Kiyota A, Mihara M, Sumida T, Kayahara H, Nakashiro K, Hamakawa H.
    Am J Clin Oncol; 2003 Oct 15; 26(5):e150-6. PubMed ID: 14528090
    [Abstract] [Full Text] [Related]

  • 19. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 20. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C, Siu LL.
    Curr Opin Oncol; 2008 May 01; 20(3):256-63. PubMed ID: 18391623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.